Table 1.
Results of MSI-H GA patients treated with ICI monotherapy.
| Study | Line | Number of MSI GA | ORR (95% CI) | PFS (95% CI) | OS (95% CI) |
|---|---|---|---|---|---|
| KEYNOTE-158 | Pembrolizumab ≥ L2 | 24 | 45.8% (25.6-67.2) | 11.0 months (2.1-NR) | NR (7.2 months-NR) |
| Marabelle et al. (13) | |||||
| KEYNOTE-062 | Pembrolizumab L1 | 14/256 | 57.1% (NA) | 11.2 months (NA) | NR (10.7 months-NR) |
| Shitara et al. (15) | |||||
| KEYNOTE-061 | Pembrolizumab L2 | 15/296 | 46.7% (NA) | 17.8 months (NA) | NR (5.6 months-NR) |
| Shitara et al. (3) |
ORR, overall response rate; PFS, progression-free survival; OS, overall survival; NR, not reached; NA, not available.